Prevention of late presentation of an HIV infection

Published: 20-06-2014 Last updated: 19-03-2025

To determine the prevalence of HIV infection in patients presenting at the ED of the Erasmus

MC, Maasstad Hospital or AMC

Ethical reviewApproved WMOStatusRecruitment stoppedHealth condition typeViral infectious disordersStudy typeObservational invasive

Summary

ID

NL-OMON40685

Source

ToetsingOnline

Brief title

HIV prevalence at the Emergency Department

Condition

Viral infectious disorders

Synonym

AIDS, HIV

Research involving

Human

Sponsors and support

Primary sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Source(s) of monetary or material Support: AIDS fonds

Intervention

Keyword: Emergency Department, HIV, prevalence

1 - Prevention of late presentation of an HIV infection 15-06-2025

Outcome measures

Primary outcome

The primary endpoint is the prevalence of HIV infections

Secondary outcome

The secondary endpoint is the HIV prevalence in different high-risk groups

Study description

Background summary

In the Netherlands, it is estimated that 30-40% of people with an HIV infection has not yet been diagnosed. In case of a later presentation the individual patient is at risk for an increased mortality and morbidity, and at the population level there is a higher transmission rate of HIV. In view of changing the treatment indication, which is becoming more and more less independent of the number of CD4 + lymphocytes, an early detection of HIV infection is of great importance in both the interests of the individual patient and the general population. In this pilot study we examine the HIV prevalence in active case finding in the Emergency Department (ED), through an opt-out system. Depending on the observed HIV prevalence, a proposal will be made for opt-out testing at all ED's in the Netherlands.

Study objective

To determine the prevalence of HIV infection in patients presenting at the ED of the Erasmus MC, Maasstad Hospital or AMC

Study design

Cross-sectional multicenter study

Study burden and risks

When blood is drawn at the ED an additional blood sample will be taken to perform an HIV test. Additionally, each participant receives a leaflet explaining the study and a short questionnaire to fill out. In case of a positive test result, the patient will be informed by us and follow-up appointments will be made.

Contacts

Public

Erasmus MC, Universitair Medisch Centrum Rotterdam

's-Gravendijkwal 230 Rotterdam 3015 CE

NL

Scientific

Erasmus MC, Universitair Medisch Centrum Rotterdam

's-Gravendijkwal 230 Rotterdam 3015 CE NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- >= 18 years of age
- Blood drawing deemed necessary by attending physician for presenting symptoms
- Informed consent

Exclusion criteria

- < 18 years of age
- No informed consent

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 18-08-2014

Enrollment: 4000

Type: Actual

Ethics review

Approved WMO

Date: 20-06-2014

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam

(Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 22242

Source: Nationaal Trial Register

Title:

In other registers

Register ID

CCMO NL48384.078.14
OMON NL-OMON22242